Zibotentan/Dapagliflozin

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Chronic Kidney Disease With High Proteinuria

Phase 2

A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria

Active, not recruitingNCT06942910

AstraZenecaChronic Kidney Disease With High Proteinuria

Start: 2025-05-07End: 2026-09-26Updated: 2026-09-02

Phase 3

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

Active, not recruitingNCT06087835

AstraZenecaChronic Kidney Disease With High Proteinuria

Start: 2023-11-07End: 2027-02-18Updated: 2026-08-19

Related Papers

Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKD.

2026-08-04

Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant‐level pooled analysis of the <scp>CANVAS</scp> and <scp>CREDENCE</scp> trials

European Journal of Heart Failure2025-01-233 citations

#2638 SGLT2i in CKD with high albuminuria: an observational real-world study

Nephrology Dialysis Transplantation2024-05-01